Radius Health Inc (NASDAQ:RDUS) – Cantor Fitzgerald lowered their FY2017 EPS estimates for Radius Health in a research note issued on Thursday. Cantor Fitzgerald analyst M. Goldstein now forecasts that the biopharmaceutical company will post earnings per share of ($5.30) for the year, down from their previous estimate of ($5.05). Cantor Fitzgerald currently has a “Buy” rating and a $58.00 price target on the stock.
A number of other analysts have also recently weighed in on RDUS. Maxim Group reaffirmed a “positive” rating on shares of Radius Health in a research report on Friday, September 29th. They noted that the move was a valuation call. Zacks Investment Research cut Radius Health from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Goldman Sachs Group reissued a “neutral” rating and issued a $45.00 price target on shares of Radius Health in a report on Friday, October 6th. Jefferies Group reduced their price target on Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a report on Friday, November 3rd. Finally, ValuEngine raised Radius Health from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company. Radius Health currently has an average rating of “Hold” and a consensus target price of $49.86.
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The business had revenue of $13.50 million during the quarter, compared to the consensus estimate of $6.90 million. During the same period last year, the firm earned ($1.07) earnings per share.
A number of institutional investors have recently added to or reduced their stakes in RDUS. Cubist Systematic Strategies LLC purchased a new position in Radius Health during the third quarter worth $110,000. Ameritas Investment Partners Inc. grew its position in shares of Radius Health by 19.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 541 shares during the period. Advisor Group Inc. grew its position in shares of Radius Health by 267.2% in the second quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,888 shares during the period. Amalgamated Bank purchased a new stake in shares of Radius Health in the second quarter valued at $211,000. Finally, Principal Financial Group Inc. grew its position in shares of Radius Health by 14.1% in the second quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock valued at $308,000 after purchasing an additional 839 shares during the period.
In other news, VP Brent Hatzis-Schoch acquired 1,778 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The stock was purchased at an average cost of $28.09 per share, with a total value of $49,944.02. Following the purchase, the vice president now directly owns 2,278 shares of the company’s stock, valued at approximately $63,989.02. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jesper Hoiland acquired 6,800 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The stock was purchased at an average cost of $29.04 per share, with a total value of $197,472.00. Following the completion of the purchase, the insider now directly owns 12,900 shares in the company, valued at $374,616. The disclosure for this purchase can be found here. Insiders purchased a total of 108,578 shares of company stock valued at $3,017,416 over the last ninety days. 15.00% of the stock is currently owned by company insiders.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.